Hawthorne, CA and Atlanta, GA, September 23, 2015 – BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions for life sciences research and clinical applications, and AKESOgen, a premier genomics services provider for clinical trials, clinical testing, and research, are excited to announce their new co-marketing partnership. Combining the expertise of the two companies will provide a complete end-to-end solution for clients seeking cytogenomic array and next-generation sequencing (NGS) services.
“Our partnership with AKESOgen provides customers with any throughput level, a proven, high quality, comprehensive system that enables them to be up and running in a short amount of time. Samples processed at AKESOgen labs and analyzed in BioDiscovery’s software are delivered to the user ready for review and reporting in one well-integrated workflow,” said Soheil Shams, Ph.D., CEO, BioDiscovery, Inc.
Data obtained from AKESOgen’s state-of-the-art laboratory is easily loaded into BioDiscovery’s powerful platform-independent, and user-friendly software solutions for analysis and reporting allowing users to easily process their samples and convert raw data into meaningful results. This collaboration provides clients with a seamless sample processing and analysis pipeline for a start to finish high quality service.
“We are excited to be working with a company such as BioDiscovery, who provide an outstanding portfolio of genomic analysis tools. We believe that our quality data generation capabilities perfectly complement BioDiscovery’s informatics solutions. Together, our joint resources will provide a complete end to end, white glove service for the genomics investigator or clinician in precision medicine” said Mark Bouzyk, Ph.D., AKESOgen’s Chief Scientific Officer.
To launch off this relationship at the 2015 ASHG Annual Meeting, Mark Bouzyk, will be at the BioDiscovery Booth #603-605 on Wednesday, Oct. 7 from 4:30 pm – 5:30 pm and Thursday, Oct. 8 from 9:00 am – 10:00 am for anyone interested in a one-on-one demo. No reservation needed.
AKESOgen offers full lab services starting with nucleic acid extraction to high-throughput microarray and next-generation sequencing for genotyping, copy number variation, and gene expression. AKESOgen also provides bio-banking services in their state of the art, 14,000 square foot facility. As a CLIA certified laboratory and state-licensed in GA, FL, and CA, AKESOgen provides highest quality clinical services that are rapid and cost-effective.
BioDiscovery’s platform-independent software packages provide a complete spectrum of data analysis solutions for gene expression (RNASeq, mRNA, miRNA) and copy number and sequence variation from microarray and NGS (WES, WGS, targeted panels) technologies. Nexus Copy Number is a user-friendly and robust software with specialized cancer specific tools and algorithms and the capability to handle large volumes of data. With its ability to integrate data from different modalities (gene expression, copy number, sequence variation), it offers a complete picture of the genomic landscape. BioDiscovery’s NxClinical increases accuracy and efficiency in molecular genetics and cytogenomics labs’ workflows. It is a multi-user system with a central database, automated and standardized processes, and integrated reference databases to provide robust and rapid interpretation and reporting of genomic variations.
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.
AKESOgen, is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com
The BioDiscovery software tools mentioned are designed to assist clinicians and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.
Client Relations Specialist